The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

Simo’s appointment may also hint at a broader productization push within OpenAI. Her background at Facebook and Instacart ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...

In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

There are 21 applicants to become the city of New Bedford’s next chief of police. Here's the process of what happens next.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...

Explore cutting-edge methods for detecting alcohol biomarkers and drugs of abuse using alternative sample matrices.

Explore how LC-MS technologies are transforming forensic and clinical toxicology by enabling comprehensive compound detection ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.